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OBJECTIVES: To investigate potential drivers of costs and cost savings when as-
sessing the budget impact of insulin administration devices (IADs) in patients with
type 2 diabetes (T2D).METHODS:AMicrosoft Excel®-basedmodel was constructed
to assess the budget impact of new reusable IADs in patients with T2D. The model
captured costs of insulin, IADs, needles, self-monitoring of blood glucose (test
strips and glucometers) and the direct medical costs of a number of diabetes com-
plications (minor and major hypoglycemia, myocardial infarction, stroke, end-
stage renal disease, blindness and amputation). Scenarios were constructed to
assess the budget impact of changes in hypoglycemia rates, compliance and insu-
lin wastage associated with a new IAD. The analyses were performed in a one
million member US healthcare plan from the payer perspective. Future costs were
discounted at 3%per annumand sensitivity analyseswere performed. RESULTS: In
a million member plan with a diabetes prevalence of 7.8% and annual diabetes
incidence of 0.52%, a hypothetical IAD capable of reducing hypoglycemia rates or
insulin wastage was projected to decrease healthcare expenditure over one and
five-year time horizons. Conversely, a hypothetical IAD capable of improving com-
pliance resulted in increased healthcare expenditure, driven by increased insulin
and needle costs. A device that conferred all of these benefits simultaneously was
found to be cost saving in the target population, resulting in a 0.62% decrease in
diabetes-related healthcare expenditure over five years. CONCLUSIONS: An IAD
capable of reducing hypoglycemic event rates and insulin wastage whilst improv-
ing compliance would likely be cost saving overall.
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OBJECTIVES: The objective of this analysis was to highlight the differences in gen-
der pain management after a total knee arthroplasty in the United States.
METHODS:We identified 103,600 TKA procedures from the Thomson Reuters Mar-
ketScan® Commercial andMedicare Claim databases from January 1, 2003 through
June 30, 2009. For these procedures, we analyzed 873,237 pharmaceutical claims for
muscle relaxants and analgesics/antipyretics for the 12-month postoperative pe-
riod. The mean direct costs were calculated for each calendar year for gender
cohorts and not inflation-adjusted. Wilcoxon-Mann-Whitney tests were run for
each year to determine statistical significance among the gender cohorts.
RESULTS: During the analysis period, we found statistically significant differences
in pharmaceutical pain management spending between male and female cohorts.
The female cohort spending averaged $464 per patient for the 12-month postoper-
ative period compared to $364 for the male cohort. This represents a 27% differ-
ence. During this same period, the average number of pharmaceutical pain man-
agement claims per TKA decreased for all cohorts but these averages exhibited
convergence in 2008 as spending bymales increased slightly. CONCLUSIONS: Pub-
lished studies have failed to agree on the correlation between gender and postop-
erative pain. A recent postoperative pain study concluded that “gender was not
found to be a consistent predictor as traditionally believed©.” However, our retro-
spective analysis of actual claim data provides a statistically significant correlation
between female gender and increased consumption of postoperativemuscle relax-
ants and analgesics for total knee arthroplasty procedures. These data may help
surgeons provide appropriate postoperative care for their TKA patients. 1Ip, Hui
Yun Vivian, Et. al, Predictors of Postoperative Pain and Analgesic Consumption: A
Qualitative Systematic Review, Anesthesiology, September 2009:11(3)657-677.Mar-
ketScan® is a trademark of Thomson Reuters (Healthcare) Inc.
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OBJECTIVES: Several studies have reported on the ability to reduce post-operative
pain following Inguinal Hernia repair by self-fixating mesh. Our study examines
the overall cost increases when post operative pain following Inguinal Hernia Re-
pair is significant enough to be reported by an ICD-9 diagnosis code. METHODS:
The Premier Perspective™ Database (PPD) was used to track hospital costs associ-
atedwith an outpatient Inguinal hernia repair between January, 2008 through June,
2010. ICD-9 diagnosis codeswere used to further identify patient with the presence
of acute or chronic post operative pain. For post discharge painmanagement strat-
egies and costs we sponsored market research with 30 surgeons who perform
Inguinal Hernia repair surgery. Responses were collected to specific pain manage-
ment strategies employed, and average per patient costs when patient reported
pain was mild, moderate, and severe. RESULTS: A total of 51,108 patients under-
going outpatient Inguinal Hernia repair were identified in the PPD during our study
timeframe. An ICD-9 diagnostic code representing acute or chronic pain was pres-
ent in 228 discharges. The mean cost per discharge for patients with diagnosis of
acute/chronic pain was $3,309, compared to $2,910 for patients without the diag-
nostic of pain. Eighty percent of the physicians surveyed reported they would
prescribe pain therapy with a cost of less than $ 100.00. For moderate pain the
breakdown was 70% less than $100.00 and for severe pain 44% indicated the costs
would be less than $100.00. CONCLUSIONS: The management of pain following
Inguinal Hernia repair increase the pre- and post- discharge costs to the hospital,
insurers and patients. In addition, costs appear to increase in relation to the sever-
ity of the pain reported. Inguinal hernia repair techniques which result in reduced
post operative pain such as using self fixating mesh have the potential to reduce
the costs associated with Inguinal Hernia repair.
PMD14
COMPARISON OF PER DISCHARGE COSTS OF THE REPAIR OF
INCISIONAL/VENTRAL HERNIAS PERFORMED WITH PERMACOL™ AND
STRATTICE™ IN THE UNITED STATES
Morseon M, Hashemi L
Covidien, Franklin, MA, USA
OBJECTIVES: Biologic graft implants are used in the repair of complex Incisional/
Ventral hernias when in the surgeon’s judgment the complexity of the hernia
and/or the patient’s risk factors indicate a biologic material provides an opportu-
nity for better outcomes than repair performedwith syntheticmeshmaterials. Our
objective was to examine the average cost per discharge of Incisional/Ventral her-
nia repair when Permacol™ and Strattice™ biological meshes were used.
METHODS: The Premier Perspective™ Database (PPD) was used to track hospital
reported costs associated with patient stays for Incisional/Ventral hernia repair
utilizing Permacol™ and Strattice™ in the 27 months from April, 2008 through
June, 2010. PPD is the largest hospital-based, service-level comparative database in
the USA providing detailed resource utilization and cost data categorized under a
patients’ principal and secondary procedure codes. ICD-9 procedure codes were
used to identify patients with Incisional/Ventral hernia repair. RESULTS: A total of
36,105 patients with a primary procedure code for Incisional/Ventral hernia repair
were identified between April, 2008 through June, 2010. Biologics were used in 4.2%
of these patients. Permacol™was used 135 patients and Strattice™was used in 287
patients. There were no significant differences in patient’s demographics between
the two groups. Mean and median cost per discharge was lower for Permacol™
cases compared to Strattice™ ($19,221 vs. $22,428 formean and $3,163 vs. $5,102 for
median). Cost of “Central Supply” accounted for approximately 50% of the overall
cost in both groups, while “Room and Board” accounted for approximately 22% of
the overall cost. CONCLUSIONS: The mean cost of the biologic implant was re-
ported as 42% higher when Strattice™ was used vs when Permacol™ was used
($6,596 vs. $4,659) in Incisional/Ventral hernia repairs. The mean overall discharge
costs was 17% higher when Strattice™ was used vs Permacol™ ($22,428 vs.
$19,221).
PMD15
ECONOMIC EVALUATION OF SELF-MONITORING OF BLOOD GLUCOSE REGIMES
PLUS CONVENTIONAL PHARMACOLOGIC TREATMENT FOR TYPE-2 DIABETIC
PATIENTS IN MEXICO: ESTIMATION BY DISCRETE EVENT SIMULATION
Zanela OO1, Cabra HA1, Muñoz DF2
1Johnson & Johnson Medical, Mexico City, D.F., Mexico, 2Instituto Tecnológico Autónomo de
México, Mexico City, D.F., Mexico
OBJECTIVES: Estimate the yearly costs attributable to and resulting from the pro-
vision of different self-monitoring of blood glucose (SMBG) regimes vs. no SMBG in
the treatment of patients with type-2 diabetes (T2D) from the Mexican public
health system perspective.METHODS: The individual experience of a patient with
T2D was simulated using a discrete event simulation built in Arena™. Patients
were created with unique, randomly assigned clinical, epidemiologic and demo-
graphic baseline characteristics, cloned 3 times, and sent to each of the SMBG
regimes considered (0, 1, 2 and 3 times daily). Clinical guidelines (ADA, ALAD) were
used to determine diabetic- and complication-specific pharmacologic treatment,
resource utilization and treatment algorithms & goals. Glycosilated hemoglobin
(HbA1c) was the main driver of disease progression, determining initial state, drug
titulation/combinations and insulin dosage. Treatment therapies include lifestyle
modifications alone, oral antidiabetics (OADs) and insulin use. Complication and
acute event development for each SMBG regime was assessed through relative
risks, taken from local published studies. All OADs and insulins were assumed to
be equally effective in reducing HbA1c. T2D-related complications and mortality
were considered. All clinical and cost datawere obtained frompublished literature.
Simulation was run with 16,000 patients for 20 years using a 4.5% annual discount
rate. Per-patient costs for selected years are shown in inflation-adjusted 2010MXP.
RESULTS: 1, 2 and 3 times daily SMBG regimes resulted in lesser costs than no
SMBG after years 1, 3 and 4, respectively. Year 5 accumulated costs for the former
were $114,099, $108,152 and $110,898, and $120,723 for no SMBG. CONCLUSIONS:
SMBG adoption yields better mid- and long-run clinical and economic outcomes
than no SMBG. Potential savings are due to fewer complications and slower disease
progression. Healthcare institutions should adopt SMBG to control HbA1c levels
and reduce the social and economic burden T2D imposes.
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OBJECTIVES: Laparoscopic thoracic procedures have often been associated with
shorter hospitalizations. However, the economic impact of laparoscopic thoracic
procedures compared to open thoracic procedures have not been fully assessed. In
this study, we examined the differences in cost and hospital length of stay for open
versus laparoscopic thoracic procedures in the United States.METHODS: The Pre-
mier Perspective™ Database (PPD) was used to estimate the incidence and costs of
laparoscopic versus open thoracic procedures in the United States. PPD is the larg-
est hospital-based database in the USA providing detailed resource utilization and
cost data. Patients with principal procedure codes for open or laparoscopic proce-
dures between January 1, 2007 through December 31, 2009 were selected. Combi-
nations of ICD-9 diagnosis codes and CPT procedure codes were used to identify
surgical site infections, hemorrhage and blood transfusions. RESULTS: A total of
22,640 patients with a primary procedure code for thoracic procedures were iden-
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